Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Metastasis regulation by PPARD expression in cancer cells
Xiangsheng Zuo, … , Anil K. Sood, Imad Shureiqi
Xiangsheng Zuo, … , Anil K. Sood, Imad Shureiqi
Published January 12, 2017
Citation Information: JCI Insight. 2017;2(1):e91419. https://doi.org/10.1172/jci.insight.91419.
View: Text | PDF
Research Article Oncology

Metastasis regulation by PPARD expression in cancer cells

  • Text
  • PDF
Abstract

Peroxisome proliferator–activated receptor–δ (PPARD) is upregulated in many major human cancers, but the role that its expression in cancer cells has in metastasis remains poorly understood. Here, we show that specific PPARD downregulation or genetic deletion of PPARD in cancer cells significantly repressed metastasis in various cancer models in vivo. Mechanistically, PPARD promoted angiogenesis via interleukin 8 in vivo and in vitro. Analysis of transcriptome profiling of HCT116 colon cancer cells with or without genetic deletion of PPARD and gene expression patterns in The Cancer Genome Atlas colorectal adenocarcinoma database identified novel pro-metastatic genes (GJA1, VIM, SPARC, STC1, SNCG) as PPARD targets. PPARD expression in cancer cells drastically affected epithelial-mesenchymal transition, migration, and invasion, further underscoring its necessity for metastasis. Clinically, high PPARD expression in various major human cancers (e.g., colorectal, lung, breast) was associated with significantly reduced metastasis-free survival. Our results demonstrate that PPARD, a druggable protein, is an important molecular target in metastatic cancer.

Authors

Xiangsheng Zuo, Weiguo Xu, Min Xu, Rui Tian, Micheline J. Moussalli, Fei Mao, Xiaofeng Zheng, Jing Wang, Jeffrey S. Morris, Mihai Gagea, Cathy Eng, Scott Kopetz, Dipen M. Maru, Asif Rashid, Russell Broaddus, Daoyan Wei, Mien-Chie Hung, Anil K. Sood, Imad Shureiqi

×

Figure 5

PPARD expression in B16-F10 cancer cells is more important for lung metastases than PPARD expression in non-cancer cells in syngeneic mice.

Options: View larger image (or click on image) Download as PowerPoint
PPARD expression in B16-F10 cancer cells is more important for lung meta...
B16-F10 melanoma cells transfected with control-shRNA or PPARD-shRNA-A (PPARD-shRNA-A-clone1 or -clone2) were injected via the tail vein into syngeneic C57BL/6 WT or heterozygous PPARD-KO mice (PPARD+/–), and lung metastasis formation was evaluated 3 weeks later. (A) PPARD mRNA expression levels, as measured by qRT-PCR, in normal lung tissues from C57BL/6 WT and PPARD+/– mice. (B) PPARD mRNA expression levels, as measured by qRT-PCR, in lung metastases from the indicated groups. (C) Numbers of lung metastases per mouse for each group (n = 10–14 per group). (D) Representative photographs of formalin-fixed lung specimens. Scale bar: 1 cm. Values in A–C are mean ± SEM. ***P < 0.0001; # P < 0.0001 compared with control-shRNA. P values were calculated with unpaired t test (A) or 2-way ANOVA (B and C).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts